PANGAEA Oncology S.A.
Industry / private company
Location:
Barcelona,
Spain (ES)
SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer (2026)
Bidard FC, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, et al.
Journal article
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (2026)
Kuemmel S, Fasching P, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau JF, et al.
Journal article